According to multiple independent sources, in the 2024 national medical insurance drug catalog adjustment, the pass rate of varieties outside the catalog that have passed formal review in the expert evaluation is less than 50%. The requirements for innovative drugs are higher than in previous years, emphasizing the need for real and reliable data. This pass rate is lower compared to last year (over 60%). (Caixin)
医药国谈目录外品种的专家评审通过率不到50% 创新药要求或提高
The expert review pass rate for varieties outside the medical insurance catalog is less than 50%, and the requirements for innovative drugs may need to be increased.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated